Abstract 9222: Tissue and Plasma Expression of WISPER lncRNA and Target Genes Correlate with Severity of Myocardial Fibrosis in Obstructive Hypertrophic Cardiomyopathy
Abstract
Purpose: Myocardial fibrosis is a key pathological driver of adverse clinical events, including sudden cardiac death and heart failure, in patients with hypertrophic cardiomyopathy (HCM). We previously identified WISPER, a novel cardiac fibroblast-specific long non-coding RNA (lncRNA), and demonstrated its association with cardiac myofibroblast activation and myocardial fibrosis. WISPER controls TIA1-related (TIAR) protein nuclear localization, thereby regulating genes associated with myofibroblast identity and extracellular matrix (ECM) remodeling. Here, we investigated whether WISPER and its target gene expression correlate with plasma levels and extent of myocardial fibrosis. Methods: We analyzed ventricular septal tissue resected during surgical myectomy from patients with obstructive HCM (oHCM), alongside matched plasma samples; plasma from healthy individuals served as controls. Myocardial tissue and plasma were evaluated using bulk RNA-sequencing and capture RNA-sequencing, respectively. Additionally, plasma samples underwent liquid chromatography-tandem mass spectrometry (LC-MS/MS) for proteomics analysis. Myocardial fibrosis severity was quantified via late gadolinium enhancement (LGE) using cardiac MRI performed near the time of myectomy and categorized into low (LGE ≤ 2%) and high (LGE ≥ 5-11%) cohorts. Results: Circulating WISPER levels were elevated in plasma from patients with oHCM compared to healthy controls (high-LGE vs healthy: 19.2-fold; low-LGE vs. healthy: 10.3-fold; Figure 1 ). Plasma WISPER expression stratified by fibrosis severity showed a 1.9-fold increase in the high-LGE group compared to the low-LGE group, indicating that a greater fibrosis burden is associated with higher circulating WISPER levels. Transcriptomic analysis of septal myectomy samples demonstrated that myocardial WISPER expression was also increased in the high- vs. low-LGE group (Figure 2) . Additionally, myocardial expression of key downstream mediators of WISPER activity was upregulated in high-LGE tissues, including CILP (2.1-fold vs. low-LGE samples), PDE5A (1.5-fold), SULF2 (1.1-fold), and SVEP1 (1.2-fold). Finally, proteomic assessment demonstrated that key targets regulated by WISPER were increased in circulation (Figure 3) , including SULF2 (9-fold vs. healthy), ASPN (18-fold), ADAMTSL2 (2-fold), and POSTN (31-fold). Conclusions: These results provide the first evidence that higher levels of circulating WISPER and its target gene expression in both plasma and cardiac tissue are associated with the extent of myocardial fibrosis in HCM. WISPER and its downstream targets may serve as viable circulating pharmacodynamic biomarkers that link cell state and gene expression with fibrosis burden. These data support the potential of precision anti-fibrotic therapies targeting WISPER as a novel therapeutic strategy for HCM patients.